加载中
NASDAQHealthcareBiotechnology
最新数据
US$13.33
+US$0.63 · +4.96%
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
前收盘价
US$13.33
+US$0.63 · +4.96%
盘前
US$13.33
US$0.00 · 0.00%
10月12日 6:29 ET
盘中时间采用ET。市场数据可能有所延迟。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日内区间
当前US$13.33
52周区间
当前US$13.33
盘中时间采用ET。市场数据可能有所延迟。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日内区间
当前US$13.33
52周区间
当前US$13.33
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8520.9万 USD | 3.7万 USD | 2072.3万 USD | 312.9万 USD | 1803.8万 USD |
| 销货成本 | 762.5万 USD | 1.41亿 USD | 9709.6万 USD | 8025.3万 USD | 6136万 USD |
| 毛利 | 7758.4万 USD | −1.41亿 USD | −7637.3万 USD | −7712.4万 USD | −4332.2万 USD |
| 研究与开发 | 1.96亿 USD | 1.41亿 USD | 9709.6万 USD | 8025.3万 USD | 6136万 USD |
| 销售、一般及管理费用 | 4906万 USD | 4657.9万 USD | 3649.4万 USD | 3290.8万 USD | 2801.1万 USD |
| 营业费用 | 2.37亿 USD | 4657.9万 USD | 3649.4万 USD | 3290.8万 USD | 2801.1万 USD |
| 利息收入 | 1947.5万 USD | 2705万 USD | 1221.1万 USD | 257.3万 USD | 13.7万 USD |
| 折旧和摊销 | 762.5万 USD | 670.5万 USD | 574.9万 USD | 388万 USD | 302万 USD |
| 营业利润 | −1.6亿 USD | −1.88亿 USD | −1.13亿 USD | −1.1亿 USD | −7133.3万 USD |
| 净利润 | −1.4亿 USD | −1.61亿 USD | −1.01亿 USD | −1.07亿 USD | −7131.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2241.42万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1532.34万0.02%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1512.25万0.15%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF658.81万0.01%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB493.15万0.05%108.2亿 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS389.51万0.01%338.69亿 USD0.31%US$78.35+0.32%
Vanguard Russell 2000 ETFVTWO371.61万0.02%180亿 USD0.06%US$112.66+0.50%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP349.23万0.13%26.06亿 USD0.20%US$66.35+1.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
